4-Aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV
- 25 February 2007
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (10) , 2879-2885
- https://doi.org/10.1016/j.bmcl.2007.02.066
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetesThe International Journal of Biochemistry & Cell Biology, 2006
- The biology of incretin hormonesCell Metabolism, 2006
- Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005Diabetologia, 2006
- Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetesExpert Opinion on Therapeutic Patents, 2005
- Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitorsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2005
- Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetesDiabetes & Metabolism, 2005
- Dipeptidyl Peptidase IV Inhibitors for the Treatment of DiabetesJournal of Medicinal Chemistry, 2004
- Prolyl peptidases: a serine protease subfamily with high potential for drug discoveryCurrent Opinion in Chemical Biology, 2003
- Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group studyThe Lancet, 2002
- Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2001